sGC stimulator BAY 41-8543 improves survival and ventricular function in a rat model of doxorubicin-induced cardiomyopathy with nephrotic syndrome.

Authors

Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba

Published in

British journal of pharmacology. Jul 24, 2026. Epub Jul 24, 2026.

Abstract

Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline-induced cardiomyopathy. This raises the hypothesis that increasing cGMP by sGC stimulation could preserve cardiac function even after HF has developed. This study aimed to evaluate the long-term effects of treatment with sGC stimulator BAY 41-8543 in a model of DOXO-induced HF with nephrotic syndrome in hypertensive rats.
Male Ren-2 transgenic rats received five weekly intravenous injections of DOXO (cumulative dose 10 mg·kg^-1) to induce cardiomyopathy. After two additional weeks, animals were treated with either BAY 41-8543 (10 mg·kg^-1·day^-1) or an ACE inhibitor (ACEi; trandolapril, 0.25 mg·kg^-1·day^-1). Echocardiography, blood and urine collection were performed at baseline (week -1) and 4 weeks after the treatment started to assess cardiac ventricular function, cardiac and renal biomarkers; survival at 20 weeks.
Treatment with BAY 41-8543 improved long-term survival, preserved left and right ventricular systolic function and reduced myocardial expression of inflammation-related genes, particularly those linked to type I interferon signalling. ACEi provided stronger benefits in survival and structural remodelling. Kidney damage and function was not improved by any treatment compared to placebo.
The sGC stimulator BAY 41-8543 exerted significant cardioprotective effects in DOXO-induced HF. Therefore, sGC stimulators may represent a promising therapeutic option for anthracycline-induced cardiomyopathy, although additional studies are required to fully investigate their therapeutic potential.

PMID:
42498692
Bibliographic data and abstract were imported from PubMed on 25 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.